Nuclera launched an antibody screening service to streamline the transition from antibody hit generation to lead selection, aiming to reduce the experimental bottleneck that slows AI-driven antibody discovery. The service uses 96-plex binary cell-free expression and binding assays to rapidly narrow large antibody libraries before expensive mammalian expression and functional testing. Nuclera said it uses Surface Plasmon Resonance on prioritized hits to characterize binding kinetics, converting early in silico hits into experimentally confirmed binders. The release follows a Series C extension that supports integration of expression and binding validation within discovery workflows. The company framed the service as a way to eliminate non-binders earlier and preserve downstream resources, especially as AI/ML approaches increase antibody candidate volumes.